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1. Introduction 
Primary membranous glomerulonephritis (MGN) is a major glomerular disease causing 
proteinuria in humans (Jones, 1957).  It is the prototype of an autoimmune disease (Couser, 
et al., 1978) characterized by sub-epithelial immune deposits within glomeruli. Its 
pathogenesis remains still unknown. Immune deposits are formed by IgG4, their respective 
antigen and complement. The definition of the immune deposit architecture has been a main 
focus of the pathology research for years but  advances were restricted, until recently, to 
animal models of the disease, in particular to Heymann nephritis (HN) (Heymann, et al., 
1959; Heymann, et al., 1952; Van Damme, et al., 1978). Unfortunately, results from 
experimental HN cannot be readily exported to human MGN since the major antigen of 
immune deposits in rat is not present in human glomeruli. Therefore different podocyte 
antigens are involved in human MGN and their identification is a fundamental step in 
understanding human pathology. Technology problems, mainly concerning dissection of 
glomeruli and purification/characterization of glomerular antibodies from human biopsies, 
have limited the experimental approach in humans for years. 
In the last 5 years, human MGN has become the topic of renewed nephrologic research. 
Debiec et al. (Debiec, et al., 2002, 2004) first showed that neutral endopeptidase (NEP) 
emerges as podocyte antigen in a rare form of congenital MGN due to maternal NEP 
deficiency and alloimmunization during pregnancy. More recently, the existence of three 
new glomerular auto-antigens, i.e. phospholipase A2 receptor (PLA2R), aldose reductase 
(AR) and superoxide dismutase 2 (SOD2) have been proposed by independent groups 
(Beck, et al., 2009; Prunotto, et al., 2010).  
Technology evolution in the field of laser capture and proteomics allowed a direct 
experimental approach in humans, a crucial step for a direct analysis ‘in vivo’. It is now clear 
that IgG4 eluted from glomeruli of MGN patients recognize a panel of podocyte proteins 
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that have been only in part characterized and that represent good candidates for being 
involved in the pathogenesis of MGN as “auto-antigens”. 
The same approach might be extended to different renal auto-immune pathologies. 
However, before proceeding, the scientific community needs a consensus on criteria and 
technologies that should be utilized for recognizing and validating auto-antigens.  
2. Animal models 
Heymann nephritis (Heymann, et al., 1952, 1959) is the animal model most frequently used 
for studying mechanisms implicated in the process of deposition of antibodies within 
glomeruli. Passive Heymann nephritis is induced in susceptible rat strains by injection of 
heterologous antisera from sheep or rabbit immunized with a crude extract of rat proximal 
tubular antigens known as Fx1A. This model is highly similar to human MGN: renal 
pathology in HN is constantly charachterized by the presence of glomerular sub-epithelial 
immune deposits. Heymann nephritis is quite simple to be produced and has offered for 
years the unique chance to study the structure of immune deposits and the mechanisms 
involved in their formation. This goal has been completed many years ago. Several studies, 
between 1980 and 1990, demonstrated that megalin is the target antigen of sub-epithelial 
IgG. Complement factors, mainly  C5b-9, and other ancillary proteins such as  receptor 
associated protein (RAP) and anti-RAP IgG complete the structure of immune deposits 
(Couser, et al., 1978; Kerjaschki, 2004; Kerjaschki & Farquhar, 1982; Kerjaschki, et al., 1987, 
1992; Saito, et al., 1994; Salant, et al., 1980a, 1980b; Van Damme, et al., 1978).  
The presence of IgG directed against a podocyte antigen triggers the complement cascade 
that ends with the formation of C5b-9, the key mediator of podocyte damage in MGN. C5b-9 
aggregation on the podocyte membrane causes the activation of the epithelial cell.  The 
podocyte starts the production of a cascade of mediators with phosphorylation of PKC and 
formation of free oxygen radicals (Cybulsky, et al., 2000). The result is a rearrangement of 
the cytoskeleton and the consequent loss of cell junction that leads to a pathologic alteration 
of the glomerular filter and to the appearance of proteinuria.  
Immune deposits also contain clusterin (Ghiggeri, et al., 2002; Rastaldi, et al., 2006), a natural 
binder of megalin, that probably represents an endogenous inhibitor of C5b-9.  
The definition of pathology features and physiopathology events in Heymann nephritis 
represented a breakthrough in research of renal autoimmunity. Unfortunately, in spite some 
of the components above have been detected in human MGN (i.e. C5b-9, clusterin), 
Heymann nephritis could not be utilized as a direct model of human MGN because megalin 
is not present in human glomeruli. Moreover, many years later, it was described that 
megalin structural homolog, the LDL-receptor, is not recognized by circulating IgG4 in 
human MGN (Bruschi, et al., 2009).  
Diverse animal models of membranous nephropathy have been developed and different 
podocyte antigens have been identified such as neutral endopeptidase in rabbit,  and 
dipeptidyl peptidase IV in mouse (Table 1) (Assmann, et al., 1992; Ronco, et al., 1989). These 
proteins are present in human glomeruli; however they were not identified in immune 
deposits and their involvement in idiopathic MGN was never proved (Allegri, 1997).  
After all, animal models showed the heterogeneity of potential podocyte antigens in MGN 
and straightened the concept of ‘in situ’ formation of immune deposit. Problems related to 
the translation of the lesson from animal models to human beings slowed progression in 
understanding of mechanisms of human MGN. After twenty years, however, new insights 
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were generated by the observation of familial models of MGN and from the characterization 
of antigens involved in their pathogenesis.  
 
 Animal Models  Ref.  
    
Megalin  rat 
Kerjaschki & 
Farquhar, 1982 
Dipeptidyl peptidase IV  rat, mouse, rabbit 
Assmann, et al., 
1992 
Neutral endopeptidase  rabbit 
Ronco, et al., 
1989 
    
 Neonatal MGN   
    
Neutral endopeptidase  humans 
Debiec, et al., 
2002 
    
 Idiopathic MGN   
    
Phospholipase A2 receptor  humans Beck, et al., 2009 
Aldose reductase  humans 
Prunotto, et al., 
2010 
Mn-superoxide dismutase  humans 
Prunotto, et al., 
2010 
Alpha enolase  humans 
Bruschi, et al., 
2011 
Others  humans 
Bruschi, et al., 
2011 
Table 1. Glomerular antigens in experimental models and in human MGN 
3. Human MGN 
3.1 Neonatal MGN 
Seminal studies by Debiec and Ronco (Debiec, et al., 2002; Debiec, et al., 2004) represented  
a fundamental passage on the road of comprehension of human MGN many years after  
the definition of HN. These authors’ contributions led to the definition of neutral 
endopeptidase as the auto-antigen in rare forms of familial congenital MGN (Table 1). 
Antibodies against neutral endopeptidase was first recognized in a newborn presenting 
with congenital nephrotic syndrome. Renal histology demonstrated MGN. The basis of the 
pathogenesis was the mother, carrying a genetic deficiency of neutral endopeptidase 
because of an homozygous deletion in MME, the corresponding gene. She became 
alloimmunized against neutral endopeptidase during a prior pregnancy, ended with 
miscarriage. Anti- neutral endopeptidase antibodies were then transferred to the fetus 
during the successive pregnancy and congenital MGN developed in the newborn while 
disappearing thereafter.  
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This elegant model could therefore demonstrate, for the first time, the pathogenic role of a 
podocyte antigen in human MGN. Similar mutations of MME were found in three further 
families that had in common at least one case of congenital MGN. Even if the presence and 
the involvement of antibodies against neutral endopeptidase was clearly demonstrated, the 
prevalence of this form of MGN is probably very low and these results cannot be translated 
directly in idiopathic MGN.  
There is, in fact, now much debate about considering neutral endopeptidase an auto-
antigen in non-familial MGN. In fact, circulating anti- neutral endopeptidase IgG4 can be 
detected in a minor part of patients with primary MGN but this antigen is not recognized 
by IgG4 eluted from micro-dissected glomeruli (Ghiggeri, personal observation). Further 
studies are required to rule out the involvement of neutral endopeptidase in idiopathic 
MGN. 
3.2 Technology advances for ‘in vivo’ studies 
New technologies in the fields of tissue micro-dissection and protein characterization have 
recently played an essential role in discovering new auto-antigen in human MGN. They 
allowed for the first time the analysis of minute amounts of human tissue from a diagnostic 
renal biopsy. In fact, micro-dissection and proteomics are of fresh development but have 
been rapidly adapted to renal tissue studies (Murtas, et al., 2011).  
The basic approach starts with  the laser dissection of glomeruli from cryo-sections of renal 
tissue. This technique is highly specific and reproducible. It permits to obtain  purified 
glomeruli from which antibodies can be eluted utilizing osmotic gradients and further 
characterizated.  
Western blot analysis coupled with mass spectrometry is the second basic technique for 
characterizing auto-antibodies. In this case, podocyte proteins are first separated with 
mono-dimensional electrophoresis in both denaturing and non-denaturing conditions (a few 
proteins are not recognized after mild denaturing treatment) or with two-dimensional gel 
electrophoresis and they are then incubated with glomerular eluates. The binding of specific 
IgG4 with podocyte antigens is detected with anti-IgG4 antibodies and revealed with 
chemiluminescence. Finally, podocyte proteins recognized by IgG4 are characterized by 
mass spectrometry. 
Western-blot/mass spectrometry are also utilized for the characterization of circulating 
antibodies: serum replaces eluted antibodies.  
3.3 Glomerular antigens in human MGN 
In terms of general discussion it is rational to propose at least three basic characteristics that 
should be fulfilled by a protein when considered as an auto-antigen in idiopathic MGN.  
The first one is that the candidate auto-antigen is expressed by podocytes at least in 
pathological conditions and that it is recognized by IgG4 eluted from micro-dissected 
glomeruli. The second criterion is that the candidate antigen co-localizes with IgG4 (and 
possibly with C5b-9) in glomerular sub-epithelial immune deposits.  The final condition is 
that IgG4 against the protein must be detected in MGN patients sera at least during the overt 
phase of the disease.  
A question apart is specificity, that is a major issue of the consensus debate.  
Therefore, characterizing an auto-antigen requires a multistep approach: first of all 
immunoglobulins are eluted from MGN glomeruli. Then their target is evaluated by 
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western-blot against podocyte proteins. The evaluation of co-localization within the immune 
deposits, isotype analysis and titration of circulating antibodies are further steps of the same 
project. Following this scheme three podocyte proteins have been characterized as putative 
auto-antigens: phospholipase A2 receptor (PLA2r), Mn-superoxide dismutase (SOD2), 
aldose reductase (AR).   Alpha enolase is a recent finding (Table 1 and Figure 1). Few others 
are still in progress. 
PLA2r is a member of the mannose-receptor family that is normally expressed on the 
podocyte membrane in humans (East & Isacke, 2002; Lambeau & Lazdunski, 1999). It binds 
circulating phospholipase A2 but its physiological role is still uncertain. In MGN auto-
antibodies recognize PLA2r only in its native configuration that is dependent on disulphide 
bonds and this is the reason why this protein requires stringent conditions of analysis 
rigorously in non-denaturing environment. It is reasonable that conformation of PLA2r 
plays a key role in auto-antibodies formation and binding. Studies (Beck, et al., 2009; 
Hofstra, et al., 2011) in limited groups of patients with idiopathic MGN revealed high 
circulating levels in a significant portion of patients and their absence in cases of secondary 
MGN suggesting a direct implication as causative factor.  
SOD2 is a key anti-oxidant mitochondrial enzyme implicated in transformation of 
superoxide ions into hydrogen peroxide and diatomic oxygen (Son, et al.,2008). In the 
kidney, SOD2 is widely expressed in tubular epithelial cells, especially in the cortex, where 
it plays a central role in preserving the kidney during ischemia/reperfusion events but it has 
never been reported in normal glomeruli. In fact, SOD2 is neo-expressed in podocytes and 
in sub-epithelial immune deposits of patients with MGN. (Figure 1) (Prunotto, et al., 2010). 
This suggests that conditions associated with hyperexpression and membrane displacement 
may be implicated in the auto-immune process.  
AR belongs to the family of aldo-keto reductases involved in catalysis of NADPH-
dependent reduction of aliphatic and aromatic aldehydes and ketones. It is usually a 
cytoplasmic enzyme. It converts glucose into sorbitol and it is involved in regulation of 
tissue tonicity and osmolarity (Williamson, et al.,1993). As for SOD2, localization of AR 
within the normal kidney is limited to tubular epithelial cells of the medulla and it is 
absent in glomeruli. In MGN patients it become detectable in glomeruli and it co-localizes 
with deposed IgG4  (Figure 1) (Barski, et al., 2005; Terubayashi, et al., 1989; Prunotto, et al. 
2010). 
The fourth antigen, alpha enolase (Bruschi, et al., 2011) is one of the most abundant proteins 
in cytosol where it participates in the glycolysis process as catalyst of the dehydration of 2-
phosphoglycerate to phosphoenolpiruvate; it is particularly expressed in tubular kidney 
cells and in liver epithelia. A plasma membrane localization has also been described. Several 
autoimmune diseases are associated with circulating anti-alpha enolase antibodies; however 
a pathogenetic role has never been demonstrated in any pathological entity   (Wistow, et al., 
1988; Miles, et al., 1991; Aaronson, et al., 1995; Sabbatini, et al., 1997; Gitlits, et al., 2001). The 
presence of this kind of auto-antibodies in sera of MGN patients is not a new finding 
(Wakui, et al., 1999). However, alpha enolase neo-expression in MGN glomeruli and its co-
localization with IgG4 straighten the concept that it is another auto antigen implicated in 
MGN pathogenesis (Figure 1).  
Glomerular immunoglobulin eluates interact with other podocyte membrane proteins 
(Figure 2). They need to be identified and they have to be tested with the approach 
described above. Probably, the list of MGN antigens will further increase in a few years.   
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Fig. 1. Glomerular expression of aldose reductase, Mn-superoxide dismutase and alpha 
enolase in MGN patients. Immunofluorescence on renal cryo-sections analyzed with 
confocal microscopy. Merged images show co-localization between antigens and IgG4. 
3.4 Antibody isotypes and clinical correlations 
IgG4 typically represents the main body of  immune deposits in both Heymann nephritis 
and human MGN. IgG1 and IgG2 are also present.  
In sera IgG4 against the described glomerular antigens are prevalent. However,  also IgG1 
can be detected in case of auto-antibodies against alpha enolase. Circulating auto-antibodies 
are made up of  the same he same IgG4/IgG1  isotypes indicating a good homology between 
the circulating and the renal counterparts (Figure 2). How the IgG isotype can influence 
pathogenesis of MGN is still matter of debate since a few issues are not clear.  The first one 
is related to the described inability of IgG4 to activate complement, that might suggests an 
independence between IgG4 deposition and C5b-9 formation. Another concern is about 
IgG1: their role in MGN need to be re-evaluated.  
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Fig. 2. (a) Circulating immunoglobulin isotypes referred to autoantibodies againsts AR, 
SOD2 and alpha enolase. In the former two cases the predominant isotype is IgG4, in the 
case of alpha enolase both IgG1 and IgG4 are detectable. (b) Western-blot with IgG4  eluted 
from glomeruli of patients with MGN. A few podocyte proteins are recognized . Three of 
them have been characterized as aldose reductase (AR), Mn-superoxide dismutase  (SOD2) 
and alpha enolase.  
The determination of circulating levels of antibodies against  auto-antigens and their clinical 
correlation is now in progress.  Only small cohorts of patients have been evaluated. 
Moreover, in each population only one antigen have been tested (Beck, et al., 2009; Prunotto, 
et al., 2010; Debiec & Ronco, 2011; Hofstra, et al. 2011). A correlation of autoantibodies level 
with proteinuria has been proposed, suggesting that high circulating titers are in 
relationship with phases of immunological activity of the disease. A strong association with 
clinical outcome is still lacking. It is also an important issue to establish a correlation among 
antibodies against different antigens; such stuidies are on the way. Probably they will help 
in establishing a hierarchy between antigens, if it exists.  
Another key aspect would be to find out a correlation between glomerular deposits and 
serum levels or clinical outome. Surrogate biomarkers are needed for guiding treatment and 
long-term follow-up in MGN patients. 
3.5 Predisposing factors 
Many immunological or infectious diseases, neoplasms and toxic or farmacological agents 
have been associated with MGN. In these situations MGN is considered “secondary” to the 
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respective pathological entity, even if the presumptive antigen has never been isolated from 
the affected glomeruli. A classical pathogenetic theory affirms that the causative agent can 
initiate the pathological process in genetically susceptible individuals.  
In primary MGN some association has been proved with HLA alleles: in particular HLA-B8, 
HLA-B18 and HLA-DR3. The latter has been described probably confering a threefold 
increased risk of the disease (Dyer, et al., 1992; Klouda, et al., 1979)  
More recently a genomewide association study conducted in three white European 
population reported an evident association of MGN with single nucleotide  polymorphism 
(SNP) in PLA2R gene and, more strongly, in HLA-DQ alpha chain 1 (HLA-DQA1). The 
authors do not report any association in AR and SOD2 genes. The MGN risk in relation with 
SNPs in PLA2R gene is proposed also in two other Asian studies (Stanescu, et al., 2011).  
Even these data are not conclusive, they might suggest a “two hits” model also for the 
pathogenesis of MN. In fact, a variation in some component of  the immune system (HLA-
DQ variation) might confer an autoimmunity predisposition. Successively, an alteration, 
congenital or acquired, of the localization or of the structure of an antigen (PLA2R or 
others), can make the antigen itself became the target of the disregulated immune system.  
4. Conclusions 
Research on MGN pathogenesis restarted recently, after many years of  frustrating findings. 
Technology evolution was the major incentive to new stuidies.   
The finding of at least four auto-antigens implicated in the pathogenesis of MGN, needs an 
explanation in a complex pathogenetic theory. Nowadays, it seems reasonable that 
mechanisms related to the formation of auto-antibodies against membrane proteins, such as 
PLA2r, are different from auto-antibodies against antigens typically localized inside the cell, 
such as SOD2 (mitochondrial), and AR or alpha enolase (cytosolic). Antibody promiscuity 
can be in some way justified by mimicry in case of membrane proteins whereas, for 
molecules such as SOD2, AR or alpha enolase, mechanisms of de-localization should play a 
role. 
Anyway, before a complete elucidation of MGN pathogenesis several studies have to be 
performed: more clinical data, new insights on cellular localization of antigens and , maybe, 
new animal models are needed.  
There is a some kind of hierarchy between different targets of autoimmunity? The 
production of a first autoantibody stimulates podocyte expression of other auto-antigens 
and a new wave of immunization? There are types of autoantibody not correlated with 
clinical evolution that are only some kind of “epiphenomenon”? There are different clusters 
of MGN patients with different autoantibody profile? 
Many questions raise when considering recent discoveries on MGN. They will be correctly 
answered only if scientific community proceeds with shared approach in discovering and 
testing candidate antigens. Exciting times are coming for the researches involved in studies 
on MGN and other renal auto-immune diseases.  
5. Acknowledgements 
This work was supported by the Italian Ministry of Health and by the Renal Child 
Foundation. Authors also acknowledge Fondazione Mara Wilma e Bianca Querci for 
financial support to the project ”Ruolo dello stress reticolare nella progressione del danno renale e 
www.intechopen.com
 
Immunological Basis of Membranous Glomerulonephritis 
 
27 
tumorale”, Fondazione La Nuova Speranza for supporting the project ‘Progetto integrato per la 
definizione dei meccanismi implicati nella glomerulo sclerosi focale. Dalla predisposizione genetica 
alla regolazione della produzione di fattori cellulari e circolanti’ and Fondazione Compagnia di 
San Paolo for the project ‘Nefropatia cronica del rene trapiantato’ 
Data were critically discussed with Prof. Rosanna Gusmano before her death and this 
chapter is dedicated to her memory.  
6. References 
Aaronson, RM; Graven, KK; Tucci, M; McDonald, RJ & Farber, HW. (1995). Non-neuronal 
enolase is an endothelial hypoxic stress protein. J Biol Chem, Vol. 270, No. 46, (Nov 
1995), pp. 27752-27757, ISSN 0021-9258 
Allegri, L. (1997). Antigens in experimental models of membranous nephropathy: are they 
involved in human disease? Nephrol Dial Transplant, Vol. 12, No. 9, (Sep 1997), pp. 
1801-1804, ISSN 0931-0509 
Assmann, KJ; van Son, JP; Dijkman, HB & Koene, RA. (1992). A nephritogenic rat 
monoclonal antibody to mouse aminopeptidase A. Induction of massive 
albuminuria after a single intravenous injection. J Exp Med, Vol. 175, No. 3, (Mar 
1992), pp. 623-635, ISSN 0022-1007 
Barski, OA; Papusha, VZ; Ivanova, MM; Rudman, DM & Finegold, MJ. (2005). 
Developmental expression and function of aldehyde reductase in proximal tubules 
of the kidney. Am J Physiol Renal Physiol, Vol. 289, No. 1, (Jul 2005), pp. F200-207, 
ISSN 0363-6127 
Beck, LH, Jr; Bonegio, RG; Lambeau, G; Beck, DM; Powell, DW; Cummins, TD; Klein, JB & 
Salant, DJ. (2009). M-type phospholipase A2 receptor as target antigen in idiopathic 
membranous nephropathy. N Engl J Med, Vol. 361, No. 1, (Jul 2009), pp. 11-21, ISSN 
1533-4406 
Bruschi, M; Candiano, G; Murtas, C; Prunotto, M; Santucci, L; Carnevali, ML; Scolari, F; 
Allegri, L & Ghiggeri, GM. (2009). Patients with primary membranous nephropathy 
lack auto-antibodies against LDL receptor, the homologue of megalin in human 
glomeruli. NDT Plus, (Jan 2009), 10.1093/ndtplus/sfp002  
Bruschi, M; Carnevali, ML; Murtas, C; Candiano, G; Petretto, A; Prunotto, M; Gatti, R; 
Argentiero, L; Magistroni, R; Garibotto, G; Scolari, F; Ravani, P; Gesualdo, L; 
Allegri, L & Ghiggeri GM. (2011). Direct characterization of target podocyte 
antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-
enolase and borderline antigens. J Proteomics, (n.d.), 10.1016/j.jprot.2011.05.021 
Couser, WG; Steinmuller, DR; Stilmant, MM; Salant, DJ & Lowenstein, LM. (1978). 
Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest, 
Vol. 62, No. 6, (Dec 1978), pp. 1275-1287, ISSN 0021-9738 
Cybulsky, AV; Takano, T; Papillon, J & McTavish, AJ. (2000). Complement-induced 
phospholipase A2 activation in experimental membranous nephropathy. Kidney Int, 
Vol. 57, No. 3, (Mar 2000), pp. 1052-1062, ISSN 0085-2538 
Debiec, H; Guigonis, V; Mougenot, B; Decobert, F; Haymann, JP; Bensman, A; Deschenes, G 
& Ronco, PM. (2002). Antenatal membranous glomerulonephritis due to anti-
neutral endopeptidase antibodies. N Engl J Med, Vol. 346, No. 26, (Jun 2002), pp. 
2053-2060, ISSN 0028-4793 
www.intechopen.com
 
An Update on Glomerulopathies – Etiology and Pathogenesis 
 
28
Debiec, H; Nauta, J; Coulet, F; van der Burg, M; Guigonis, V; Schurmans, T; de Heer, E; 
Soubrier, F; Janssen, F & Ronco, P. (2004). Role of truncating mutations in MME 
gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet, Vol. 
364, No. 9441, (Oct 2004), pp. 1252-1259, ISSN 0140-6736 
Debiec, H & Ronco, P. (2011). PLA2R autoantibodies and PLA2R glomerular deposits in 
membranous nephropathy. N Engl J Med, Vol. 364, No. 7, (Feb 2011), pp. 689-690, 
ISSN 1533-4406 
Dyer, PA; Short, CD; Clarke, EA & Mallick, NP. (1992). HLA antigen and gene 
polymorphisms and haplotypes established by family studies in membranous 
nephropathy. Nephrol Dial Transplant, Vol. 7 Suppl 1, pp. 42-47, ISSN 0931-0509  
East, L & Isacke, CM. (2002). The mannose receptor family. Biochim Biophys Acta, Vol. 1572, 
No. 2-3, (Sep 2002), pp. 364-386, ISSN 0006-3002 
Ghiggeri, GM; Bruschi, M; Candiano, G; Rastaldi, MP; Scolari, F; Passerini, P; Musante, L; 
Pertica, N; Caridi, G; Ferrario, F; Perfumo, F & Ponticelli, C. (2002). Depletion of 
clusterin in renal diseases causing nephrotic syndrome. Kidney Int, Vol. 62, No. 6, 
(Dec 2002), pp. 2184-2194, ISSN 0083-2538 
Gitlits, VM; Toh, BH & Sentry, JW. (2001). Disease association, origin, and clinical relevance 
of autoantibodies to the glycolytic enzyme enolase. J Investig Med, Vol. 49, No. 2, 
(Mar 2001), pp. 138-45, ISSN 1081-5589 
Heymann, W; Hackel, DB; Harwood, S; Wilson, SG & Hunter, JL. (1959). Production of 
nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc 
Soc Exp Biol Med, Vol. 100, No. 4, (Apr 1959), pp. 660-664, ISSN 0037-9727  
Heymann, W; Lund, HZ & Hackel, DB. (1952). The nephrotic syndrome in rats; with special 
reference to the progression of the glomerular lesion and to the use of nephrotoxic 
sera obtained from ducks. J Lab Clin Med, Vol. 39, No. 2, (Feb 1952), pp. 218-224, 
ISSN 0022-2143 
Hofstra, JM; Beck, LH Jr; Beck, DM; Wetzels, JF & Salant, DJ. (2011). Anti-Phospholipase A2 
Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous 
Nephropathy. Clin J Am Soc Nephrol, (n.d.), ISSN 1555-905X (Electronic) 
Jones, DB. (1957). Nephrotic glomerulonephritis. Am J Pathol, Vol. 33, No. 2, (Mar-Apr 1957), 
pp. 313-329, ISSN 0002-9440  
Kerjaschki, D. (2004). Pathomechanisms and molecular basis of membranous 
glomerulopathy. Lancet, Vol. 364, No. 9441, (Oct 2004), pp. 1194-1196, ISSN 0140-
6736 
Kerjaschki, D & Farquhar, MG. (1982). The pathogenic antigen of Heymann nephritis is a 
membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad 
Sci U S A, Vol. 79, No. 18, (Sep 1982), pp. 5557-5561, ISSN 0027-8424 
Kerjaschki, D; Horvat, R; Binder, S; Susani, M; Dekan, G; Ojha, PP; Hillemanns, P; Ulrich, W 
& Donini, U. (1987). Identification of a 400-kd protein in the brush borders of 
human kidney tubules that is similar to gp330, the nephritogenic antigen of rat 
Heymann nephritis. Am J Pathol, Vol. 129, No. 1, (Oct 1987), pp. 183-191, ISSN 0002-
9440 
Kerjaschki, D; Ullrich, R; Diem, K; Pietromonaco, S; Orlando, RA & Farquhar, MG. (1992). 
Identification of a pathogenic epitope involved in initiation of Heymann nephritis. 




Immunological Basis of Membranous Glomerulonephritis 
 
29 
Klouda, PT; Manos, J; Acheson, EJ; Dyer, PA; Goldby, FS; Harris, R; Lawler, W; Mallick, NP 
& Williams, G. (1979). Strong association between idiopathic membranous 
nephropathy and HLA-DRW3. Lancet, Vol. 2, No. 8146, (Oct 1979), pp. 770-771, 
ISSN 0140-6736 
Lambeau, G & Lazdunski, M. (1999). Receptors for a growing family of secreted 
phospholipases A2. Trends Pharmacol Sci, Vol. 20, No. 4, (Apr 1999), pp. 162-170, 
ISSN 0165-6147 
Miles, LA: Dahlberg, CM; Plescia, J; Felez, J; Kato, K & Plow, EF. (1991). Role of cell-surface 
lysines in plasminogen binding to cells: identification of alpha-enolase as a 
candidate plasminogen receptor. Biochemistry, Vol. 30, No. 6, (Feb 1991), pp. 1682-
1691, ISSN 0006-2960 
Murtas, C; Bruschi, M; Carnevali, ML; Petretto, A; Corradini, E; Prunotto, M; Candiano, G; 
Degl'innocenti, ML; Ghiggeri, GM & Allegri, L.  (2011). In vivo characterization of 
renal auto-antigens involved in human auto-immune diseases: The case of 
membranous glomerulonephritis. Proteomics Clin Appl, Vol. 5, No. 1-2, (Feb 2011), 
pp. 90-97, ISSN 1862-8354 
Prunotto, M; Carnevali, ML; Candiano, G; Murtas, C; Bruschi, M; Corradini, E; Trivelli, A; 
Magnasco, A; Petretto, A; Santucci, L; Mattei, S; Gatti, R; Scolari, F; Kador, P; 
Allegri, L &  Ghiggeri, GM. (2010). Autoimmunity in membranous nephropathy 
targets aldose reductase and SOD2. J Am Soc Nephrol, Vol. 21, No. 3, (Mar 2010), pp. 
507-519, ISSN 1533-3450 
Rastaldi, MP; Candiano, G; Musante, L; Bruschi, M; Armelloni, S; Rimoldi, L; Tardanico, R; 
Sanna-Cherchi, S; Ferrario, F; Montinaro, V; Haupt, R; Parodi, S; Carnevali, ML; 
Allegri, L; Camussi, G; Gesualdo, L; Scolari, F & Ghiggeri, GM. (2006). Glomerular 
clusterin is associated with PKC-alpha/beta regulation and good outcome of 
membranous glomerulonephritis in humans. Kidney Int, Vol. 70, No. 3, (Aug 2006), 
pp. 477-485, ISSN 0085-2538 
Ronco, P; Allegri, L; Brianti, E; Chatelet, F; Van Leer, EH & Verroust, P. (1989). Antigenic 
targets in epimembranous glomerulonephritis. Experimental data and potential 
application in human pathology. Appl Pathol, Vol. 7, No. 2, pp. 85-98, ISSN 0252-
1172 
Sabbatini, A; Dolcher, MP; Marchini, B; Chimenti, D; Moscato, S; Pratesi, F; Bombardieri, S 
& Migliorini, P. (1997). Alpha-enolase is a renal-specific antigen associated with 
kidney involvement in mixed cryoglobulinemia. Clin Exp Rheumatol, Vol. 15, No. 6, 
(Nov-Dec 1997), pp. 655-658, ISSN 0392-856X 
Saito, A; Pietromonaco, S; Loo, AK & Farquhar, MG. (1994). Complete cloning and 
sequencing of rat gp330/"megalin," a distinctive member of the low density 
lipoprotein receptor gene family. Proc Natl Acad Sci U S A, Vol. 91, No. 21, (Oct 
1994), pp. 9725-9729, ISSN 0027-8424 
Salant, DJ; Belok, S; Madaio, MP & Couser, WG. (1980a). A new role for complement in 
experimental membranous nephropathy in rats. J Clin Invest, Vol. 66, No. 6, (Dec 
1980), pp. 1339-1350, ISSN 0021-9738 
Salant, DJ; Darby, C & Couser, WG. (1980b). Experimental membranous glomerulonephritis 
in rats. Quantitative studies of glomerular immune deposit formation in isolated 
glomeruli and whole animals. J Clin Invest, Vol. 66, No. 1, (Jul 1980), pp. 71-81 
www.intechopen.com
 
An Update on Glomerulopathies – Etiology and Pathogenesis 
 
30
Son, D; Kojima, I; Inagi, R; Matsumoto, M; Fujita, T & Nangaku, M. (2008). Chronic hypoxia 
aggravates renal injury via suppression of Cu/Zn-SOD: a proteomic analysis. Am J 
Physiol Renal Physiol, Vol. 294, No. 1, (Jan 2008), pp. F62-72, ISSN 0363-6127 
Stanescu, HC; Arcos-Burgos, M; Medlar, A; Bockenhauer, D; Kottgen, A; Dragomirescu, L; 
Voinescu, C; Patel, N; Pearce, K; Hubank, M; Stephens, HA; Laundy, V; 
Padmanabhan, S; Zawadzka, A; Hofstra, JM; Coenen, MJ; den Heijer, M; Kiemeney, 
LA; Bacq-Daian, D; Stengel, B; Powis, SH; Brenchley, P; Feehally, J; Rees, AJ; 
Debiec, H; Wetzels, JF; Ronco, P; Mathieson, PW & Kleta, R. (2011). Risk HLA-
DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med, 
Vol. 364, No. 7, (Feb 2011), pp. 616-626, ISSN 1533-4406 
Terubayashi, H; Sato, S; Nishimura, C; Kador, PF & Kinoshita, JH. (1989). Localization of 
aldose and aldehyde reductase in the kidney. Kidney Int, Vol. 36, No. 5, (Nov 1989), 
pp. 843-851, ISSN 0085-2538 
Van Damme, BJ; Fleuren, GJ; Bakker, WW; Vernier, RL & Hoedemaeker, PJ. (1978). 
Experimental glomerulonephritis in the rat induced by antibodies directed against 
tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous 
immune complex glomerulonephritis. Lab Invest, Vol. 38, No. 4, (Apr 1978), pp. 502-
510, ISSN 0023-6837  
Williamson, JR; Chang, K; Frangos, M; Hasan, KS; Ido, Y; Kawamura, T; Nyengaard, JR; van 
den Enden, M; Kilo, C & Tilton, RG. (1993). Hyperglycemic pseudohypoxia and 
diabetic complications. Diabetes, Vol. 42, No. 6, (Jun 1993), pp. 801-813, ISSN 0012-
1797 
Wakui, H; Imai, H; Komatsuda, A &  Miura, AB. (1999). Circulating antibodies against 
alpha-enolase in patients with primary membranous nephropathy (MN). Clin Exp 
Immunol, Vol. 118, No. 3, (Dec 1999), pp. 445-50, ISSN 0009-9104 
Wistow, GJ; Lietman, T; Williams, LA; Stapel, SO; de Jong, WW; Horwitz, J & Piatigorsky, J. 
(1988). Tau-crystallin/alpha-enolase: one gene encodes both an enzyme and a lens 
structural protein. J Cell Biol, Vol. 107, No. 6 Pt 2, (Dec 1988), pp. 2729-2736, ISSN 
0021-9525 
www.intechopen.com
An Update on Glomerulopathies - Etiology and Pathogenesis
Edited by Prof. Sharma Prabhakar
ISBN 978-953-307-388-0
Hard cover, 276 pages
Publisher InTech
Published online 06, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The book has fourteen chapters which are grouped under different sections: Immune System and
Glomerulonephritis, Animal Models of Glomerulonephritis, Cytokines and Signalling Pathways, Role of Cells
and Organelles in Glomerulonephritis and Miscellaneous. While the purpose of this volume is to serve as an
update on recent advances in the etio-pathogenesis of glomerulopathies, the book offers the current and
broad based knowledge in the field to readers of all levels in the nephrology community.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Gian Marco Ghiggeri, Corrado Murtas, Maria Luisa Carnevali, Giovanni Candiano, Maurizio Bruschi, Marco
Prunotto, Riccardo Magistroni and Landino Allegri (2011). Immunological Basis of Membranous
Glomerulonephritis, An Update on Glomerulopathies - Etiology and Pathogenesis, Prof. Sharma Prabhakar
(Ed.), ISBN: 978-953-307-388-0, InTech, Available from: http://www.intechopen.com/books/an-update-on-
glomerulopathies-etiology-and-pathogenesis/immunological-basis-of-membranous-glomerulonephritis
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
